Maturation of dendritic cells (DCs) from healthy donors or from breast cancer patients
2011-12-31T00:01:51Z (GMT) by
<p><b>Copyright information:</b></p><p>Taken from "Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency"</p><p>Breast Cancer Research 2005;7(3):R326-R335.</p><p>Published online 25 Feb 2005</p><p>PMCID:PMC1143555.</p><p>Copyright © 2005 Gervais et al.; licensee BioMed Central Ltd</p> Data are expressed as the percentage of the cells (with standard error) expressing the CD80, CD83 and CD86 surface markers after treatment of immature DCs with a combination of maturating agents: tumour necrosis factor (TNF)-α/lipopolysaccharide (LPS)/CD40L (= 3); IL-1β/IL-6/TNF-α/prostaglandin (PG)E(= 4–5); and Ribomunyl/Imukin(= 3). Different from corresponding donors in each individual assay.